#United States #Class Action #San Francisco #ClaimsFiler #Iovance Biotherapeutics

Iovance Biotherapeutics Shareholder Alert: Important Deadline Approaching

In an important reminder for shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ClaimsFiler, a free service dedicated to shareholder information, has announced that investors have until July 15, 2025, to file their lead plaintiff applications related to a securities class action lawsuit against the company. This legal action affects those who purchased Iovance’s securities between May 9, 2024, and May 8, 2025. The case is currently pending in the United States District Court for the Northern District of California. 

Who Should Take Action?

If you are an investor who sustained losses exceeding $100,000 due to your investment in Iovance during the specified period, it is crucial to act promptly. ClaimsFiler encourages affected shareholders to visit their website at ClaimsFiler or call their toll-free number, 844-367-9658, for further assistance and guidance on your legal options. Legal representatives from Kahn Swick & Foti, LLC are on hand to discuss potential next steps for investors wishing to pursue this action.

Background of the Lawsuit

The core allegations in this lawsuit center on Iovance and its executives’ failure to disclose crucial information during the class action period, thereby violating federal securities laws. A significant trigger for this legal action followed Iovance's release of its Q1 2025 financial results on May 8, 2025. The company reported a total product revenue of $49.3 million, reflecting a staggering drop from $73.7 million in the previous quarter. Furthermore, they issued a major revision to their projected fiscal year 2025 revenue, slashing their guidance from a range of $450 million - $475 million down to $250 million - $300 million. The updated forecast was attributed to the dynamics observed with the recent launch of Amtagvi, including a reassessment based on growth trajectories and treatment timelines for new authorized treatment centers (ATCs).

This pronounced downturn in performance prompted a dramatic 44.8% decline in Iovance's share price the following day, from $1.42 to $1.75, a notable drop influenced by unusually high trading volume. Investors rightfully concerned about their financial stakes in Iovance during this tumultuous period are looking for recourse.

Next Steps for Investors

As part of the class action suit, current shareholders should not delay in filing their applications for lead plaintiff status. Not only could this provide a path towards financial recovery, but it also encourages accountability from the executives implicated in the allegations.

About ClaimsFiler

ClaimsFiler is dedicated to assisting retail investors in recovering lost funds from securities class action settlements. Their website offers free registration for users to access crucial information regarding settlements and filing processes. Additionally, investors are encouraged to upload their portfolio transactional data to receive timely notifications about relevant securities cases in which they may have vested interests. For assistance and free case evaluations, investors can also direct inquiries to the legal team at Kahn Swick & Foti, LLC. To learn more about their services, please visit ClaimsFiler.com.

In short, Iovance shareholders are urged to take swift action before the deadline approaches. The potential for financial recovery remains firm for those willing to pursue their legal rights in this ongoing matter.

• ---

For further updates on the situation surrounding Iovance Biotherapeutics and its effect on shareholders, stay tuned to ClaimsFiler.